Twitxy
Saved
@nellage's profile picture
View on X

Kornelia Polyak

@nellage

Dana-Farber Cancer Institute @DanaFarber, Harvard Medical School @harvardmed, @MSKCancerCenter, Weill Cornell @WeillCornell, Johns Hopkins @hopkinskimmel
Boston polyaklab.dana-farber.org Joined April 2008
376 Following 553 Followers 453 Posts

Latest posts 5

Kornelia Polyak @nellage
Happy to share our new manuscript: Whole-genome doubling drives immune evasion by silencing antigen presentation: Cancer Cell cell.com/cancer-cell/fu… @LabPolyak @DFCI_BreastOnc @oesterreichs @Adrianvlee @ZheqiL
www.cell.com Whole-genome doubling drives immune evasion by silencing antigen presentation Foidart et al. reveal that whole-genome doubling (WGD) promotes immune suppression in breast cancer. WGD+ tumors have diminished expression of antigen presentation and reduced IFNγ response. Metabo...
4 replies 17 reposts 72 likes 4.1K views View on X
Kornelia Polyak @nellage
Identification of cycling regulatory T cell precursors as conductors of immune escape during breast carcinoma progression: Cancer Cell cell.com/cancer-cell/fu…
www.cell.com Identification of cycling regulatory T cell precursors as conductors of immune escape during breast... Bui et al. map immune escape from DCIS to IBC by using single-cell transcriptomic profiling of large clinical cohorts, identifying cycTreg as key IL-33-driven immune suppressors supported by height...
Kornelia Polyak @nellage
HER2 heterogeneous breast cancer models reveal novel therapeutic targets and subclonal dynamics during evolution to resistance to HER2-targeted therapies aacrjournals.org/cancerdiscover…
aacrjournals.org HER2 Heterogeneous Breast Cancer Models Reveal Novel Therapeutic Targets and Subclonal Dynamics... In HER2-heterogeneous breast cancer, ERBB2–non-amplified cells with low HER2 expression promote recurrence after T-DXd treatment, and combination therapies that enhance T-Dxd efficacy in these cells...
Kornelia Polyak @nellage
HER2 heterogeneous breast cancer models reveal novel therapeutic targets and subclonal dynamics during evolution to resistance to HER2-targeted therapies aacrjournals.org/cancerdiscover… @LabPolyak @DFCI_BreastOnc
aacrjournals.org HER2 Heterogeneous Breast Cancer Models Reveal Novel Therapeutic Targets and Subclonal Dynamics... In HER2-heterogeneous breast cancer, ERBB2–non-amplified cells with low HER2 expression promote recurrence after T-DXd treatment, and combination therapies that enhance T-Dxd efficacy in these cells...